Emerging targeted therapies for melanoma. - Wikidata - wikimedia - TriplyDB

Emerging targeted therapies for melanoma.

Emerging targeted therapies for melanoma.

http://www.wikidata.org/entity/Q38826425

about

Methods of selecting combination therapy for colorectal cancer patients: a patent evaluation of US20160025730A1.Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors.

P2860

Q38709385-6A219C7A-6AED-4737-8669-07B1432E32A5 Q38948950-5AEA8DB8-48CF-4FF9-8461-4C97A14D6334

P2860

Emerging targeted therapies for melanoma.

http://www.wikidata.org/entity/Q38826425

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Emerging targeted therapies for melanoma.

@en

type

label

Emerging targeted therapies for melanoma.

@en

prefLabel

Emerging targeted therapies for melanoma.

@en

P1433

Q38826425-4C0D1944-822B-4B58-A116-975D144E979C

P1476

Q38826425-8C9C1142-F5EE-4E2D-AE51-5756A5B14CD6

P2093

Q38826425-42ADA596-E1A4-4A32-8008-F9A0AA684BDA

Q38826425-6CE0E555-E6A3-4553-93CF-5EC068DF1E65

Q38826425-A9171AF2-571A-4D42-813F-17591F8A7317

P2860

Q38826425-01AEC93F-DBF1-4C5B-AE43-9259657F53D5

Q38826425-06968ECE-4855-450F-809A-358DF1B5A08A

Q38826425-12C8D606-ED8B-436E-88DC-F94E2972B799

Q38826425-1744EC3E-1F23-4195-B17A-D6ECDAE27522

Q38826425-2265287B-C741-4D48-A332-F5C8B7357622

Q38826425-24C0B711-FF46-4918-9A7A-EB08728DFB9B

Q38826425-26FD30F8-1454-4691-8365-E352FFA9A252

Q38826425-2CEFA1D7-9AAC-4895-A4A6-1F5791449EBB

Q38826425-3405A8E5-6E7D-4147-B2B7-3FD4C797138A

Q38826425-382DDBCC-436C-4DC7-A75F-70C5908D98C5

P304

Q38826425-21CD87D5-B29B-4C5E-877F-B9DACD8420F4

P31

Q38826425-6E2E8B25-1435-46F8-9F04-000206CC93BD

Q38826425-6e4d4efd-17b8-47ef-ae35-4f68f7ceba10

P356

Q38826425-027234D4-790D-4942-9870-8DF9D8872121

P407

Q38826425-C0381B2D-38A0-4BD8-BF68-6D5A3B7B7F64

P433

Q38826425-1749F648-470D-4417-AAAA-7109559FF0C7

P478

Q38826425-76821A34-438D-44B6-B55C-28B88F8266B4

P577

Q38826425-9417BA5C-A135-4ABC-86D6-D6E82E5A55F4

P698

Q38826425-98E7C328-8C74-4B96-B348-3D176E15F48B

P356

14728214.2016.1184644

P1433

Expert Opinion on Emerging Drugs

P1476

Emerging targeted therapies for melanoma.

@en

P2093

Douglas B Johnson

http://www.w3.org/2001/XMLSchema#string

Jeffrey A Sosman

http://www.w3.org/2001/XMLSchema#string

Megan H Pollack

http://www.w3.org/2001/XMLSchema#string

P2860

A landscape of driver mutations in melanoma

Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma

Mutations in GNA11 in uveal melanoma

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi

MEK and PI3K inhibition in solid tumors: rationale and evidence to date

Design and synthesis of novel allosteric MEK inhibitor CH4987655 as an orally available anticancer agent

RAF inhibitors that evade paradoxical MAPK pathway activation

Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification.

P304

195-207

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14728214.2016.1184644

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P577

2016-05-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27148822

http://www.w3.org/2001/XMLSchema#string